ΠŸΠΎΠΌΠΎΡ‰ΡŒ Π² ΡƒΡ‡Ρ‘Π±Π΅, ΠΎΡ‡Π΅Π½ΡŒ быстро...
Π Π°Π±ΠΎΡ‚Π°Π΅ΠΌ вмСстС Π΄ΠΎ ΠΏΠΎΠ±Π΅Π΄Ρ‹

ΠŸΠΎΠ»ΡƒΡ‡Π΅Π½ΠΈΠ΅ ΠΈ исслСдованиС Π»Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½Π° Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ°, синтСзируСмого с ΠΌΠΎΠ»ΠΎΠΊΠΎΠΌ трансгСнных ΠΌΡ‹ΡˆΠ΅ΠΉ

Π”ΠΈΡΡΠ΅Ρ€Ρ‚Π°Ρ†ΠΈΡΠŸΠΎΠΌΠΎΡ‰ΡŒ Π² Π½Π°ΠΏΠΈΡΠ°Π½ΠΈΠΈΠ£Π·Π½Π°Ρ‚ΡŒ ΡΡ‚ΠΎΠΈΠΌΠΎΡΡ‚ΡŒΠΌΠΎΠ΅ΠΉ Ρ€Π°Π±ΠΎΡ‚Ρ‹

Π’ ΡΠΎΠ²Ρ€Π΅ΠΌΠ΅Π½Π½ΠΎΠΉ ΠΌΠ΅Π΄ΠΈΡ†ΠΈΠ½Π΅ большоС Π²Π½ΠΈΠΌΠ°Π½ΠΈΠ΅ удСляСтся биологичСски Π°ΠΊΡ‚ΠΈΠ²Π½Ρ‹ΠΌ Π±Π΅Π»ΠΊΠ°ΠΌ Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° ΠΊΠ°ΠΊ лСкарствСнным срСдствам. Π’Π°ΠΊΠΈΠ΅ Π±Π΅Π»ΠΊΠΈ высокоэффСктивны ΠΈ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡ‡Π΅ΡΠΊΠΈ бСзопасны. К ΠΈΡ… Ρ‡ΠΈΡΠ»Ρƒ относятся Ρ€Π°Π·Π»ΠΈΡ‡Π½Ρ‹Π΅ Π³ΠΎΡ€ΠΌΠΎΠ½Ρ‹, Ρ„Π΅Ρ€ΠΌΠ΅Π½Ρ‚Ρ‹, Ρ„Π°ΠΊΡ‚ΠΎΡ€Ρ‹ свёртываСмости ΠΊΡ€ΠΎΠ²ΠΈ, роста Ρ‚ΠΊΠ°Π½Π΅ΠΉ ΠΈ Π΄Ρ€. БущСствСнным прСпятствиСм Π½Π° ΠΏΡƒΡ‚ΠΈ развития Π½ΠΎΠ²ΠΎΠΉ области Ρ„Π°Ρ€ΠΌΠ°Ρ†Π΅Π²Ρ‚ΠΈΠΊΠΈ являСтся практичСская Π½Π΅Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡ‚ΡŒ получСния Π½Π΅ΠΎΠ±Ρ…ΠΎΠ΄ΠΈΠΌΡ‹Ρ…… Π§ΠΈΡ‚Π°Ρ‚ΡŒ Π΅Ρ‰Ρ‘ >

Π‘ΠΎΠ΄Π΅Ρ€ΠΆΠ°Π½ΠΈΠ΅

  • 1. ΠžΠ±Π·ΠΎΡ€ Π»ΠΈΡ‚Π΅Ρ€Π°Ρ‚ΡƒΡ€Ρ‹
    • 1. 1. ВрансгСнныС ΠΆΠΈΠ²ΠΎΡ‚Π½Ρ‹Π΅. Бпособы получСния ΠΈ ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΠΎΠ²Π°Π½ΠΈΡ
    • 1. 2. Π›Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½. Π‘Ρ‚Ρ€ΡƒΠΊΡ‚ΡƒΡ€Π° ΠΈ Ρ„ΡƒΠ½ΠΊΡ†ΠΈΠΈ
    • 1. 3. ΠŸΠ΅Ρ€ΡΠΏΠ΅ΠΊΡ‚ΠΈΠ²Ρ‹ ΠΈ Π°ΠΊΡ‚ΡƒΠ°Π»ΡŒΠ½ΠΎΡΡ‚ΡŒ Ρ‚Π΅ΠΌΡ‹ диссСртации
  • 2. ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Ρ‹ ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹ исслСдований
    • 2. 1. ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Ρ‹
    • 2. 2. ΠœΠ΅Ρ‚ΠΎΠ΄Ρ‹
  • 3. Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ ΠΈ ΠΎΠ±ΡΡƒΠΆΠ΄Π΅Π½ΠΈΠ΅
    • 3. 1. ΠŸΠΎΠ»ΡƒΡ‡Π΅Π½ΠΈΠ΅ ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½Ρ‹Ρ… трансгСнных ΠΌΡ‹ΡˆΠ΅ΠΉ
    • 3. 2. Π’ΠΊΠ°Π½Π΅ΡΠΏΠ΅Ρ†ΠΈΡ„ΠΈΡ‡Π½ΠΎΡΡ‚ΡŒ экспрСссии трансгСна
    • 3. 3. ΠŸΠ΅Ρ€Π΅Π΄Π°Ρ‡Π° трансгСна Π² Ρ€ΡΠ΄Ρƒ ΠΏΠΎΠΊΠΎΠ»Π΅Π½ΠΈΠΉ трансгСнных ΠΌΡ‹ΡˆΠ΅ΠΉ
    • 3. 4. ΠŸΡ€ΠΎΠ΄ΡƒΠΊΡ†ΠΈΡ Ρ€Π΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½Ρ‚Π½ΠΎΠ³ΠΎ Π»Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½Π° Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° с ΠΌΠΎΠ»ΠΎΠΊΠΎΠΌ ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½Ρ‹Ρ… трансгСнных самок ΠΈ Π΄ΠΎΡ‡Π΅Ρ€Π΅ΠΉ ΠΎΡ‚ ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½Ρ‹Ρ… трансгСнных самцов ΠΌΡ‹ΡˆΠΈ
    • 3. 5. Π–ΠΈΠ²ΠΎΡ‚Π½Ρ‹Π΅ с Π½Π΅ΠΎΠ±Ρ‹Ρ‡Π½ΠΎ высоким ΡƒΡ€ΠΎΠ²Π½Π΅ΠΌ ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ†ΠΈΠΈ Ρ€Π΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½Ρ‚Π½ΠΎΠ³ΠΎ Π»Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½Π° Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° с ΠΌΠΎΠ»ΠΎΠΊΠΎΠΌ
    • 3. 6. ΠŸΡ€ΠΎΠ΄ΡƒΠΊΡ†ΠΈΡ Ρ€Π΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½Ρ‚Π½ΠΎΠ³ΠΎ Π»Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½Π° Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° Π² ΠΏΠΎΠΊΠΎΠ»Π΅Π½ΠΈΡΡ… трансгСнных ΠΏΠΎ Π³Π΅Π½Ρƒ Π»Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½Π° Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° ΠΌΡ‹ΡˆΠ΅ΠΉ Π² Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡ‚ΠΈ ΠΎΡ‚ Π»ΠΈΠ½ΠΈΠΈ, конструкции, копийности Π²ΡΡ‚Ρ€ΠΎΠΈΠ²ΡˆΠ΅Π³ΠΎΡΡ трансгСна
    • 3. 7. ΠŸΡ€ΠΎΠ΄ΡƒΠΊΡ†ΠΈΡ Ρ€Π΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½Ρ‚Π½ΠΎΠ³ΠΎ Π»Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½Π° Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° с ΠΌΠΎΠ»ΠΎΠΊΠΎΠΌ трансгСнных самок ΠΌΡ‹ΡˆΠΈ Π² Ρ‚Π΅Ρ‡Π΅Π½ΠΈΠ΅ ΠΏΠ΅Ρ€ΠΈΠΎΠ΄Π° Π»Π°ΠΊΡ‚Π°Ρ†ΠΈΠΈ
    • 3. 8. Π€ΠΈΠ·ΠΈΠΊΠΎ-химичСскиС ΠΈ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡ‡Π΅ΡΠΊΠΈΠ΅ свойства Ρ€Π΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½Ρ‚Π½ΠΎΠ³ΠΎ Π»Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½Π° Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° ΠΈΠ· ΠΌΠΎΠ»ΠΎΠΊΠ° трансгСнных ΠΌΡ‹ΡˆΠ΅ΠΉ
    • 3. 9. ΠŸΠ°Ρ‚ΠΎΠΌΠΎΡ€Ρ„ΠΎΠ»ΠΎΠ³ΠΈΡ‡Π΅ΡΠΊΠΈΠΉ ΠΈ Π³ΠΈΡΡ‚ологичСский Π°Π½Π°Π»ΠΈΠ· трансгСнных ΠΌΡ‹ΡˆΠ΅ΠΉ
  • Π’Ρ‹Π²ΠΎΠ΄Ρ‹

ΠŸΠΎΠ»ΡƒΡ‡Π΅Π½ΠΈΠ΅ ΠΈ исслСдованиС Π»Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½Π° Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ°, синтСзируСмого с ΠΌΠΎΠ»ΠΎΠΊΠΎΠΌ трансгСнных ΠΌΡ‹ΡˆΠ΅ΠΉ (Ρ€Π΅Ρ„Π΅Ρ€Π°Ρ‚, курсовая, Π΄ΠΈΠΏΠ»ΠΎΠΌ, ΠΊΠΎΠ½Ρ‚Ρ€ΠΎΠ»ΡŒΠ½Π°Ρ)

Π’ ΡΠΎΠ²Ρ€Π΅ΠΌΠ΅Π½Π½ΠΎΠΉ ΠΌΠ΅Π΄ΠΈΡ†ΠΈΠ½Π΅ большоС Π²Π½ΠΈΠΌΠ°Π½ΠΈΠ΅ удСляСтся биологичСски Π°ΠΊΡ‚ΠΈΠ²Π½Ρ‹ΠΌ Π±Π΅Π»ΠΊΠ°ΠΌ Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° ΠΊΠ°ΠΊ лСкарствСнным срСдствам. Π’Π°ΠΊΠΈΠ΅ Π±Π΅Π»ΠΊΠΈ высокоэффСктивны ΠΈ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡ‡Π΅ΡΠΊΠΈ бСзопасны. К ΠΈΡ… Ρ‡ΠΈΡΠ»Ρƒ относятся Ρ€Π°Π·Π»ΠΈΡ‡Π½Ρ‹Π΅ Π³ΠΎΡ€ΠΌΠΎΠ½Ρ‹, Ρ„Π΅Ρ€ΠΌΠ΅Π½Ρ‚Ρ‹, Ρ„Π°ΠΊΡ‚ΠΎΡ€Ρ‹ свёртываСмости ΠΊΡ€ΠΎΠ²ΠΈ, роста Ρ‚ΠΊΠ°Π½Π΅ΠΉ ΠΈ Π΄Ρ€. БущСствСнным прСпятствиСм Π½Π° ΠΏΡƒΡ‚ΠΈ развития Π½ΠΎΠ²ΠΎΠΉ области Ρ„Π°Ρ€ΠΌΠ°Ρ†Π΅Π²Ρ‚ΠΈΠΊΠΈ являСтся практичСская Π½Π΅Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡ‚ΡŒ получСния Π½Π΅ΠΎΠ±Ρ…ΠΎΠ΄ΠΈΠΌΡ‹Ρ… Π±Π΅Π»ΠΊΠΎΠ² ΠΈΠ· ΠΆΠΈΠ΄ΠΊΠΎΡΡ‚Π΅ΠΉ ΠΈ Ρ‚ΠΊΠ°Π½Π΅ΠΉ самого Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° Π² ΠΏΡ€ΠΎΠΌΡ‹ΡˆΠ»Π΅Π½Π½Ρ‹Ρ… ΠΌΠ°ΡΡˆΡ‚Π°Π±Π°Ρ…. Π’ ΡΠ²ΡΠ·ΠΈ с ΡΡ‚ΠΈΠΌ Π² ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΠ΅ дСсятилСтия для получСния лСкарствСнных Π±Π΅Π»ΠΊΠΎΠ² Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° использовались биотСхнологичСскиС ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹, Π³Π»Π°Π²Π½Ρ‹ΠΌ ΠΎΠ±Ρ€Π°Π·ΠΎΠΌ, ΠΌΠΈΠΊΡ€ΠΎΠ±Π½Ρ‹ΠΉ синтСз. Π’ ΠΊΠ°Ρ‡Π΅ΡΡ‚Π²Π΅ ΠΏΡ€ΠΎΠ΄ΡƒΡ†Π΅Π½Ρ‚ΠΎΠ² лСкарствСнных Π±Π΅Π»ΠΊΠΎΠ² Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° Ρ‚Π°ΠΊΠΆΠ΅ ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΡƒΡŽΡ‚ водоросли, Π²Ρ‹ΡΡˆΠΈΠ΅ растСния, Π³Ρ€ΠΈΠ±Ρ‹. Π’Π°ΠΊΠΈΠΌ ΠΏΡƒΡ‚Ρ‘ΠΌ Π±Ρ‹Π»ΠΈ ΠΏΠΎΠ»ΡƒΡ‡Π΅Π½Ρ‹ инсулин, ΠΈΠ½Ρ‚Π΅Ρ€Ρ„Π΅Ρ€ΠΎΠ½Ρ‹, Π½Π΅ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Π΅ Ρ„Π°ΠΊΡ‚ΠΎΡ€Ρ‹ свёртываСмости ΠΊΡ€ΠΎΠ²ΠΈ ΠΈ Ρ€ΡΠ΄ иммуномодуляторов. К ΡΠΎΠΆΠ°Π»Π΅Π½ΠΈΡŽ, Π½ΠΈ ΠΎΠ΄Π½Π° ΠΈΠ· ΡΡ‚ΠΈΡ… биотСхнологичСских систСм Π½Π΅ ΡΠΌΠΎΠ³Π»Π° Π² ΠΏΠΎΠ»Π½ΠΎΠΉ ΠΌΠ΅Ρ€Π΅ ΠΎΠ±Π΅ΡΠΏΠ΅Ρ‡ΠΈΡ‚ΡŒ ΠΈΠ΄Π΅Π½Ρ‚ΠΈΡ‡Π½ΠΎΡΡ‚ΡŒ Ρ€Π΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½Ρ‚Π½Ρ‹Ρ… Π±Π΅Π»ΠΊΠΎΠ² Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° ΠΏΡ€ΠΈΡ€ΠΎΠ΄Π½Ρ‹ΠΌ, Π² Ρ‡Π°ΡΡ‚ности, Π½Π΅ΠΎΠ±Ρ…ΠΎΠ΄ΠΈΠΌΡ‹Π΅ посттрансляционныС ΠΌΠΎΠ΄ΠΈΡ„ΠΈΠΊΠ°Ρ†ΠΈΠΈ структуры Π±Π΅Π»ΠΊΠ°. ΠšΡ€Π°ΠΉΠ½Π΅ слоТным оказался процСсс очистки Ρ‚Π°ΠΊΠΈΡ… Ρ€Π΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½Ρ‚Π½Ρ‹Ρ… Π±Π΅Π»ΠΊΠΎΠ². Π˜Ρ… ΠΏΡ€ΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ Π½Π΅Ρ€Π΅Π΄ΠΊΠΎ ΡΠΎΠΏΡ€ΠΎΠ²ΠΎΠΆΠ΄Π°Π»ΠΎΡΡŒ аллСргичСскими рСакциями Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ². ΠšΡ€ΠΎΠΌΠ΅ Ρ‚ΠΎΠ³ΠΎ, Ρ‚Π°ΠΊΠΎΠ΅ производство лСкарствСнных Π±Π΅Π»ΠΊΠΎΠ² Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° оказалось экологичСски ΠΏΡ€ΠΎΠ±Π»Π΅ΠΌΠ½Ρ‹ΠΌ. Π’ Ρ€ΡΠ΄Π΅ стран ΠΎΠ½ΠΎ постСпСнно выводится ΠΈΠ· Ρ…озяйствСнного обращСния. ΠŸΡ€ΠΎΠ±Π»Π΅ΠΌΡƒ получСния Ρ€Π΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½Ρ‚Π½Ρ‹Ρ… Π±Π΅Π»ΠΊΠΎΠ² Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° ΠΏΡ‹Ρ‚Π°ΡŽΡ‚ΡΡ Ρ€Π΅ΡˆΠΈΡ‚ΡŒ с ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΊΡƒΠ»ΡŒΡ‚ΠΈΠ²ΠΈΡ€ΡƒΠ΅ΠΌΡ‹Ρ… соматичСских ΠΊΠ»Π΅Ρ‚ΠΎΠΊ, ΠΎΠ΄Π½Π°ΠΊΠΎ этот ΠΏΡƒΡ‚ΡŒ Π΄Π»ΠΈΡ‚Π΅Π»Π΅Π½ ΠΈ Π΄ΠΎΡ€ΠΎΠ³ΠΎΡΡ‚оящ.

Π’ ΡΠ²ΡΠ·ΠΈ с ΡΡ‚ΠΈΠΌ Π²ΠΎΠ·Π½ΠΈΠΊΠ»Π° идСя ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΠΎΠ²Π°Ρ‚ΡŒ Π² ΠΊΠ°Ρ‡Π΅ΡΡ‚Π²Π΅ Π±ΠΈΠΎΡ€Π΅Π°ΠΊΡ‚ΠΎΡ€ΠΎΠ² лСкарствСнных Π±Π΅Π»ΠΊΠΎΠ² Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° трансгСнных ΡΠ΅Π»ΡŒΡΠΊΠΎΡ…ΠΎΠ·ΡΠΉΡΡ‚Π²Π΅Π½Π½Ρ‹Ρ… ΠΆΠΈΠ²ΠΎΡ‚Π½Ρ‹Ρ…, Π² Ρ‡Π°ΡΡ‚ности, ΠΏΡ€ΠΎΠ΄ΡƒΡ†ΠΈΡ€ΡƒΡŽΡ‰ΠΈΡ… эти Π±Π΅Π»ΠΊΠΈ с ΠΌΠΎΠ»ΠΎΠΊΠΎΠΌ. ИсслСдования Π² ΡΡ‚ΠΎΠΌ Π½Π°ΠΏΡ€Π°Π²Π»Π΅Π½ΠΈΠΈ ΡˆΠΈΡ€ΠΎΠΊΠΈΠΌ Ρ„Ρ€ΠΎΠ½Ρ‚ΠΎΠΌ вСдутся Π² Ρ€ΡΠ΄Π΅ ΠΈΠ½Π΄ΡƒΡΡ‚Ρ€ΠΈΠ°Π»ΡŒΠ½ΠΎ Ρ€Π°Π·Π²ΠΈΡ‚Ρ‹Ρ… стран. Π’ Ρ€Π°Π·Ρ€Π°Π±ΠΎΡ‚ΠΊΠ΅ находятся Π±ΠΎΠ»Π΅Π΅ 50 лСкарствСнных Π±Π΅Π»ΠΊΠΎΠ² 3 Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ°, для ΠΎΠ΄Π½ΠΈΡ… ΠΈΠ· ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Ρ… ΠΏΠΎΠ»ΡƒΡ‡Π΅Π½Ρ‹ трансгСнныС ΠΆΠΈΠ²ΠΎΡ‚Π½Ρ‹Π΅, для Π΄Ρ€ΡƒΠ³ΠΈΡ… проводятся доклиничСскиС ΠΈΠ»ΠΈ клиничСскиС испытания.

НСсмотря Π½Π° ΠΎΡ‚Π΄Π΅Π»ΡŒΠ½Ρ‹Π΅ практичСскиС достиТСния, ΠΏΡ€ΠΎΠ±Π»Π΅ΠΌΠ° получСния лСкарствСнных Π±Π΅Π»ΠΊΠΎΠ² Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° с ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ трансгСнных ΠΆΠΈΠ²ΠΎΡ‚Π½Ρ‹Ρ… нуТдаСтся Π² Π³Π»ΡƒΠ±ΠΎΠΊΠΎΠΉ Π½Π°ΡƒΡ‡Π½ΠΎΠΉ ΠΏΡ€ΠΎΡ€Π°Π±ΠΎΡ‚ΠΊΠ΅. Π’ Ρ‡ΠΈΡΠ»Π΅ Π΅Ρ‘ Π°ΠΊΡ‚ΡƒΠ°Π»ΡŒΠ½Ρ‹Ρ… вопросов находится Π³Π΅Π½Π½ΠΎΠ΅ конструированиС, тСхнология получСния трансгСнных ΠΆΠΈΠ²ΠΎΡ‚Π½Ρ‹Ρ…, обСспСчСниС экспрСссии Π³Π΅Π½ΠΎΠ² интСрСса ΠΈ ΠΏΠ΅Ρ€Π΅Π΄Π°Ρ‡Π° этого ΠΏΡ€ΠΈΠ·Π½Π°ΠΊΠ° Π² Ρ€ΡΠ΄Ρƒ ΠΏΠΎΠΊΠΎΠ»Π΅Π½ΠΈΠΉ, ΠΏΠΎΠ»ΡƒΡ‡Π΅Π½ΠΈΠ΅ ΠΏΡ€ΠΎΠΌΡ‹ΡˆΠ»Π΅Π½Π½Ρ‹Ρ… стад ΠΆΠΈΠ²ΠΎΡ‚Π½Ρ‹Ρ…-ΠΏΡ€ΠΎΠ΄ΡƒΡ†Π΅Π½Ρ‚ΠΎΠ².

ЦСль Ρ€Π°Π±ΠΎΡ‚Ρ‹:

ΠŸΠΎΠ»ΡƒΡ‡Π΅Π½ΠΈΠ΅ ΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΊΠ»ΡŽΡ‡Π΅Π²ΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ° Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ°, ΠΎΠ±Π΅ΡΠΏΠ΅Ρ‡ΠΈΠ²Π°ΡŽΡ‰Π΅Π³ΠΎ Π°Π½Ρ‚ΠΈΠ±Π°ΠΊΡ‚Π΅Ρ€ΠΈΠ°Π»ΡŒΠ½ΡƒΡŽ Π·Π°Ρ‰ΠΈΡ‚Ρƒ Π΄Π΅Ρ‚Π΅ΠΉ Ρ€Π°Π½Π½Π΅Π³ΠΎ возраста — Π»Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½Π° ΠΈΠ· ΠΌΠΎΠ»ΠΎΠΊΠ° трансгСнных ΠΌΡ‹ΡˆΠ΅ΠΉ, Π²Ρ‹Π±ΠΎΡ€ ΠΎΠΏΡ‚ΠΈΠΌΠ°Π»ΡŒΠ½Ρ‹Ρ… Π³Π΅Π½Π½Ρ‹Ρ… конструкций, ΠΎΠ±Π΅ΡΠΏΠ΅Ρ‡ΠΈΠ²Π°ΡŽΡ‰ΠΈΡ… ΠΌΠ°ΠΊΡΠΈΠΌΠ°Π»ΡŒΠ½ΡƒΡŽ ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ†ΠΈΡŽ ΠΏΠΎΠ»Π½ΠΎΡ†Π΅Π½Π½ΠΎΠ³ΠΎ Π»Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½Π° Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° с ΠΌΠΎΠ»ΠΎΠΊΠΎΠΌ трансгСнных ΠΆΠΈΠ²ΠΎΡ‚Π½Ρ‹Ρ… ΠΈ ΠΏΠ΅Ρ€Π΅Π΄Π°Ρ‡Ρƒ Ρ€Π΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½Ρ‚Π½ΠΎΠ³ΠΎ Π³Π΅Π½Π° ΠΏΠΎΡΠ»Π΅Π΄ΡƒΡŽΡ‰ΠΈΠΌ поколСниям ΠΏΡ€ΠΈ сохранСнии Π·Π΄ΠΎΡ€ΠΎΠ²ΡŒΡ ΠΆΠΈΠ²ΠΎΡ‚Π½Ρ‹Ρ…-ΠΏΡ€ΠΎΠ΄ΡƒΡ†Π΅Π½Ρ‚ΠΎΠ².

Π—Π°Π΄Π°Ρ‡ΠΈ:

1. ΠŸΠΎΠ»ΡƒΡ‡ΠΈΡ‚ΡŒ ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½Ρ‹Ρ… трансгСнных ΠΏΠΎ Ρ€Π°Π·Π»ΠΈΡ‡Π½Ρ‹ΠΌ конструкциям с Π³Π΅Π½ΠΎΠΌ Π»Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½Π° Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° ΠΌΡ‹ΡˆΠ΅ΠΉ.

2. Π’Ρ‹Π±Ρ€Π°Ρ‚ΡŒ Π³Π΅Π½Π½ΡƒΡŽ ΠΊΠΎΠ½ΡΡ‚Ρ€ΡƒΠΊΡ†ΠΈΡŽ, ΠΎΠ±Π΅ΡΠΏΠ΅Ρ‡ΠΈΠ²Π°ΡŽΡ‰ΡƒΡŽ Π½Π°ΠΈΠ±ΠΎΠ»ΡŒΡˆΡƒΡŽ ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ†ΠΈΡŽ Ρ€Π΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½Ρ‚Π½ΠΎΠ³ΠΎ Π»Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½Π° Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° с ΠΌΠΎΠ»ΠΎΠΊΠΎΠΌ трансгСнных ΠΌΡ‹ΡˆΠ΅ΠΉ.

3. ΠŸΡ€ΠΎΡΠ»Π΅Π΄ΠΈΡ‚ΡŒ ΠΏΠ΅Ρ€Π΅Π΄Π°Ρ‡Ρƒ трансгСна Π² Ρ€ΡΠ΄Ρƒ ΠΏΠΎΠΊΠΎΠ»Π΅Π½ΠΈΠΉ ΠΆΠΈΠ²ΠΎΡ‚Π½Ρ‹Ρ….

4. ΠžΠΏΡ€Π΅Π΄Π΅Π»ΠΈΡ‚ΡŒ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΡƒ ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ†ΠΈΠΈ Ρ€Π΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½Ρ‚Π½ΠΎΠ³ΠΎ Π»Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½Π° Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° Π½Π° ΠΏΡ€ΠΎΡ‚яТСнии ΠΏΠ΅Ρ€ΠΈΠΎΠ΄Π° Π»Π°ΠΊΡ‚Π°Ρ†ΠΈΠΈ.

5. ΠžΠΏΡ€Π΅Π΄Π΅Π»ΠΈΡ‚ΡŒ соотвСтствиС Ρ€Π΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½Ρ‚Π½ΠΎΠ³ΠΎ Π»Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½Π° ΠΊ Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° ΠΏΡ€ΠΈΡ€ΠΎΠ΄Π½ΠΎΠΌΡƒ ΠΏΠΎ Ρ„ΠΈΠ·ΠΈΠΊΠΎ-химичСским ΠΈ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡ‡Π΅ΡΠΊΠΈΠΌ свойствам.

6. ΠžΠΏΡ€Π΅Π΄Π΅Π»ΠΈΡ‚ΡŒ влияниС трансгСна Π»Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½Π° Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° Π½Π° ΡΠΎΡΡ‚ояниС Π·Π΄ΠΎΡ€ΠΎΠ²ΡŒΡ трансгСнных ΠΌΡ‹ΡˆΠ΅ΠΉ.

7. ΠžΠΏΡ€Π΅Π΄Π΅Π»ΠΈΡ‚ΡŒ ΠΏΠ΅Ρ€ΡΠΏΠ΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ получСния ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½Ρ‹Ρ… трансгСнных ΡΠ΅Π»ΡŒΡΠΊΠΎΡ…ΠΎΠ·ΡΠΉΡΡ‚Π²Π΅Π½Π½Ρ‹Ρ… ΠΆΠΈΠ²ΠΎΡ‚Π½Ρ‹Ρ… — ΠΏΡ€ΠΎΠ΄ΡƒΡ†Π΅Π½Ρ‚ΠΎΠ² Ρ€Π΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½Ρ‚Π½ΠΎΠ³ΠΎ Π»Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½Π° Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° — Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ исслСдованных гСнСтичСских конструкций.

Новизна ΠΈ Π΄ΠΎΡΡ‚ΠΎΠ²Π΅Ρ€Π½ΠΎΡΡ‚ΡŒ ΠΏΡ€Π΅Π΄Π»ΠΎΠΆΠ΅Π½Π½Ρ‹Ρ… ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠ² ΠΈ Ρ€Π΅ΡˆΠ΅Π½ΠΈΠΉ ΠΌΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»ΠΎΠ² диссСртационной Ρ€Π°Π±ΠΎΡ‚Ρ‹.

УстановлСно, Ρ‡Ρ‚ΠΎ Π²Ρ‹Π±Ρ€Π°Π½Π½Ρ‹Π΅ Π³Π΅Π½Π½Ρ‹Π΅ конструкции ΠΎΠ±Π΅ΡΠΏΠ΅Ρ‡ΠΈΠ²Π°ΡŽΡ‚ высокий, экономичСски Π·Π½Π°Ρ‡ΠΈΠΌΡ‹ΠΉ ΡƒΡ€ΠΎΠ²Π΅Π½ΡŒ ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ†ΠΈΠΈ Ρ€Π΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½Ρ‚Π½ΠΎΠ³ΠΎ Π»Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½Π° Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° с ΠΌΠΎΠ»ΠΎΠΊΠΎΠΌ трансгСнных ΠΌΡ‹ΡˆΠ΅ΠΉ. Π‘Ρ€Π΅Π΄Π½ΠΈΠΉ ΡƒΡ€ΠΎΠ²Π΅Π½ΡŒ ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ†ΠΈΠΈ Ρ€Π΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½Ρ‚Π½ΠΎΠ³ΠΎ Π»Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½Π° Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° для Π»ΡƒΡ‡ΡˆΠ΅ΠΉ Π³Π΅Π½Π½ΠΎΠΉ конструкции Π² Ρ€ΡΠ΄Ρƒ ΠΏΠΎΠΊΠΎΠ»Π΅Π½ΠΈΠΉ трансгСнных ΠΆΠΈΠ²ΠΎΡ‚Π½Ρ‹Ρ… составил 16,7 Π³/Π». Π£ ΠΎΡ‚Π΄Π΅Π»ΡŒΠ½Ρ‹Ρ… ΠΆΠΈΠ²ΠΎΡ‚Π½Ρ‹Ρ… установлСн высокий ΡƒΡ€ΠΎΠ²Π΅Π½ΡŒ ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ†ΠΈΠΈ Ρ€Π΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½Ρ‚Π½ΠΎΠ³ΠΎ Π»Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½Π° Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° с ΠΌΠΎΠ»ΠΎΠΊΠΎΠΌ Π΄ΠΎ 40 Π³/Π». Π’ ΠΎΠ΄Π½ΠΎΠΉ ΠΈΠ· Π»ΠΈΠ½ΠΈΠΉ трансгСнных ΠΌΡ‹ΡˆΠ΅ΠΉ ΠΎΠ±Π½Π°Ρ€ΡƒΠΆΠ΅Π½Ρ‹ особи с Π½Π΅ΠΎΠ±Ρ‹Ρ‡Π½ΠΎ высоким ΡƒΡ€ΠΎΠ²Π½Π΅ΠΌ ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ†ΠΈΠΈ Π»Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½Π° Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° ΠΎΡ‚ 80 Π΄ΠΎ 160 Π³/Π». ΠžΠΏΡ€Π΅Π΄Π΅Π»Π΅Π½Π° Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠ° ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ†ΠΈΠΈ Ρ€Π΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½Ρ‚Π½ΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ° Π² Ρ‚Π΅Ρ‡Π΅Π½ΠΈΠ΅ ΠΏΠ΅Ρ€ΠΈΠΎΠ΄Π° Π»Π°ΠΊΡ‚Π°Ρ†ΠΈΠΈ ΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π° ΠΏΠ΅Ρ€Π΅Π΄Π°Ρ‡Π° трансгСна Π΄ΠΎ 8-Π³ΠΎ поколСния ΠΎΡ‚ ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½Ρ‹Ρ… трансгСнных ΠΆΠΈΠ²ΠΎΡ‚Π½Ρ‹Ρ…. Для ΠΌΡ‹ΡˆΠ΅ΠΉ, ΠΊΠ°ΠΊ Π²ΠΈΠ΄Π° ΠΌΠ½ΠΎΠ³ΠΎΠΏΠ»ΠΎΠ΄Π½Ρ‹Ρ… ΠΆΠΈΠ²ΠΎΡ‚Π½Ρ‹Ρ…, установлСно, Ρ‡Ρ‚ΠΎ с ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ самцов ΠΈ ΡΠ°ΠΌΠΎΠΊ, трансгСнных ΠΏΠΎ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡƒΠ΄Π°Ρ‡Π½Ρ‹ΠΌ Π³Π΅Π½Π½Ρ‹ΠΌ конструкциям, ΠΌΠΎΠΆΠ½ΠΎ ΠΏΠΎΠ»ΡƒΡ‡ΠΈΡ‚ΡŒ Ρ…Π°Ρ€Π°ΠΊΡ‚Π΅Ρ€ΠΈΠ·ΡƒΡŽΡ‰Π΅Π΅ΡΡ Ρ‚Π°ΠΊΠΈΠΌΠΈ ΠΆΠ΅ свойствами потомство. Показано соотвСтствиС Ρ€Π΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½Ρ‚Π½ΠΎΠ³ΠΎ Π»Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½Π° ΠΏΡ€ΠΈΡ€ΠΎΠ΄Π½ΠΎΠΌΡƒ ΠΏΠΎ ΠΎΡΠ½ΠΎΠ²Π½Ρ‹ΠΌ Ρ„ΠΈΠ·ΠΈΠΊΠΎ-химичСским показатСлям ΠΈ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡ‡Π΅ΡΠΊΠΈΠΌ свойствам.

ΠŸΡ€Π°ΠΊΡ‚ΠΈΡ‡Π΅ΡΠΊΠ°Ρ ΠΈ Π½Π°ΡƒΡ‡Π½Π°Ρ Π·Π½Π°Ρ‡ΠΈΠΌΠΎΡΡ‚ΡŒ, полоТСния, выносимыС Π½Π° Π·Π°Ρ‰ΠΈΡ‚Ρƒ.

ΠŸΠΎΠ»ΡƒΡ‡Π΅Π½Ρ‹ Π½ΠΎΠ²Ρ‹Π΅ ΠΌΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Ρ‹, Ρ…Π°Ρ€Π°ΠΊΡ‚Π΅Ρ€ΠΈΠ·ΡƒΡŽΡ‰ΠΈΠ΅ ΡΠΊΡΠΏΡ€Π΅ΡΡΠΈΡŽ Π³Π΅Π½ΠΎΠ² Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° Ρƒ Ρ‚рансгСнных ΠΆΠΈΠ²ΠΎΡ‚Π½Ρ‹Ρ…. Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ Ρ€Π°Π±ΠΎΡ‚Ρ‹ Ρ€Π΅Π°Π»ΠΈΠ·ΠΎΠ²Π°Π½Ρ‹ ΠΏΡ€ΠΈ Π²Ρ‹ΠΏΠΎΠ»Π½Π΅Π½ΠΈΠΈ ΠΏΡ€ΠΎΠ³Ρ€Π°ΠΌΠΌ Боюзного государства России ΠΈ Π‘Сларуси.

БСлРосВрансгСн" ΠΈ «Π‘СлРосВрансгСн-2». Π£ΡΠΎΠ²Π΅Ρ€ΡˆΠ΅Π½ΡΡ‚Π²ΠΎΠ²Π°Π½Π½Ρ‹Π΅ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹ создания ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½Ρ‹Ρ… трансгСнных ΠΆΠΈΠ²ΠΎΡ‚Π½Ρ‹Ρ… ΠΏΡ€ΠΈ Π»ΠΈΡ‡Π½ΠΎΠΌ участии соискатСля 5 ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΠΎΠ²Π°Π½Ρ‹ ΠΏΡ€ΠΈ ΠΏΠΎΠ»ΡƒΡ‡Π΅Π½ΠΈΠΈ ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½Ρ‹Ρ… трансгСнных ΡΠ΅Π»ΡŒΡΠΊΠΎΡ…ΠΎΠ·ΡΠΉΡΡ‚Π²Π΅Π½Π½Ρ‹Ρ… ΠΆΠΈΠ²ΠΎΡ‚Π½Ρ‹Ρ…, Ρ‡Ρ‚ΠΎ ΠΏΡ€ΠΈΠ²Π΅Π»ΠΎ ΠΊ Ρ€ΠΎΠΆΠ΄Π΅Π½ΠΈΡŽ трансгСнных ΠΊΠΎΠ·Π»ΠΎΠ² Π›Π°ΠΊ-1 ΠΈ Π›Π°ΠΊ-2, нСсущих Π² ΡΠ²ΠΎΡ‘ΠΌ Π³Π΅Π½ΠΎΠΌΠ΅ Π³Π΅Π½ Π»Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½Π° Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ°. ΠŸΠΎΠΏΡƒΠ»ΡΡ†ΠΈΠΎΠ½Π½Ρ‹Π΅ исслСдования трансгСнных ΠΌΡ‹ΡˆΠ΅ΠΉ Π±ΡƒΠ΄ΡƒΡ‚ ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΠΎΠ²Π°Π½Ρ‹ ΠΏΡ€ΠΈ ΠΏΠ»Π°Π½ΠΈΡ€ΠΎΠ²Π°Π½ΠΈΠΈ создания стад трансгСнных ΡΠ΅Π»ΡŒΡΠΊΠΎΡ…ΠΎΠ·ΡΠΉΡΡ‚Π²Π΅Π½Π½Ρ‹Ρ… ΠΆΠΈΠ²ΠΎΡ‚Π½Ρ‹Ρ…ΠΏΡ€ΠΎΠΌΡ‹ΡˆΠ»Π΅Π½Π½Ρ‹Ρ… ΠΏΡ€ΠΎΠ΄ΡƒΡ†Π΅Π½Ρ‚ΠΎΠ² Ρ€Π΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½Ρ‚Π½Ρ‹Ρ… Π±Π΅Π»ΠΊΠΎΠ² Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ°.

Π’ ΠΏΡ€ΠΎΡ†Π΅ΡΡΠ΅ выполнСния диссСртационной Ρ€Π°Π±ΠΎΡ‚Ρ‹:

β€’ ОбслСдовано 67 ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½Ρ‹Ρ… трансгСнных ΠΏΠΎ ΠΊΠΎΠ½ΡΡ‚рукциям с Π³Π΅Π½ΠΎΠΌ Π»Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½Π° Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° ΠΌΡ‹ΡˆΠ΅ΠΉ.

β€’ УстановлСно, Ρ‡Ρ‚ΠΎ ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΠΎΠ²Π°Π½Π½Ρ‹Π΅ конструкции с Π³Π΅Π½ΠΎΠΌ Π»Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½Π° Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° ΠΎΠ±Π΅ΡΠΏΠ΅Ρ‡ΠΈΠ²Π°ΡŽΡ‚ Ρ‚ΠΊΠ°Π½Π΅ΡΠΏΠ΅Ρ†ΠΈΡ„ΠΈΡ‡Π½ΡƒΡŽ ΡΠΊΡΠΏΡ€Π΅ΡΡΠΈΡŽ трансгСна.

β€’ ΠŸΠΎΠ»ΡƒΡ‡Π΅Π½ΠΎ 3885 ΠΏΠΎΡ‚ΠΎΠΌΠΊΠΎΠ² ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½Ρ‹Ρ… трансгСнных ΠΌΡ‹ΡˆΠ΅ΠΉ Π΄ΠΎ 8-Π³ΠΎ поколСния.

β€’ ΠžΠΏΡ€Π΅Π΄Π΅Π»Ρ‘Π½ ΡƒΡ€ΠΎΠ²Π΅Π½ΡŒ ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ†ΠΈΠΈ Ρ€Π΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½Ρ‚Π½ΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ° Π² Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡ‚ΠΈ ΠΎΡ‚ ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΠΎΠ²Π°Π½Π½ΠΎΠΉ гСнСтичСской конструкции, количСства ΠΊΠΎΠΏΠΈΠΉ Π²ΡΡ‚Ρ€ΠΎΠΈΠ²ΡˆΠ΅Π³ΠΎΡΡ трансгСна, дня Π»Π°ΠΊΡ‚Π°Ρ†ΠΈΠΈ ΠΈ Π²ΠΎΠ·Ρ€Π°ΡΡ‚Π° Π»Π°ΠΊΡ‚ΠΈΡ€ΡƒΡŽΡ‰Π΅ΠΉ самки ΠΌΡ‹ΡˆΠ΅ΠΉ.

β€’ ΠŸΡ€ΠΎΠ²Π΅Π΄Π΅Π½ΠΎ сравнСниС свойств Ρ€Π΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½Ρ‚Π½ΠΎΠ³ΠΎ Π»Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½Π°, Π²Ρ‹Π΄Π΅Π»Π΅Π½Π½ΠΎΠ³ΠΎ ΠΈΠ· ΠΌΠΎΠ»ΠΎΠΊΠ° трансгСнных ΠΌΡ‹ΡˆΠ΅ΠΉ ΠΈ ΠΏΡ€ΠΈΡ€ΠΎΠ΄Π½ΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ° Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ°.

β€’ ΠžΠΏΡ€Π΅Π΄Π΅Π»Π΅Π½Π° пСрспСктива получСния Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ исслСдованных конструкций ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½Ρ‹Ρ… трансгСнных ΠΊΠΎΠ·.

Апробация Ρ€Π°Π±ΠΎΡ‚Ρ‹ ΠΈ Π»ΠΈΡ‡Π½Ρ‹ΠΉ Π²ΠΊΠ»Π°Π΄ соискатСля.

Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ Ρ€Π°Π±ΠΎΡ‚Ρ‹ прСдставлСны Π½Π° ΠΌΠ΅ΠΆΠ΄ΡƒΠ½Π°Ρ€ΠΎΠ΄Π½ΠΎΠΉ ΠΊΠΎΠ½Ρ„Π΅Ρ€Π΅Π½Ρ†ΠΈΠΈ «Π›Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½» (Π³. Ницца, Ѐранция, 2007), «Π›Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½» (Π³. ПСкин, ΠšΠΈΡ‚Π°ΠΉ, 2009) ΠΈ Π½Π° Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΌ симпозиумС «Π‘Π΅Π»ΠΊΠΈ ΠΈ ΠΏΠ΅ΠΏΡ‚ΠΈΠ΄Ρ‹» (Π³. Казань, Россия, 2009).

Π‘ΠΎΠΈΡΠΊΠ°Ρ‚Π΅Π»ΡŒ ΠΏΡ€ΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡ€ΠΎΠ²Π°Π» Π»ΠΈΡ‚Π΅Ρ€Π°Ρ‚ΡƒΡ€Ρƒ ΠΏΠΎ Ρ‚Π΅ΠΌΠ΅ исслСдования, осущСствил ΠΏΠ»Π°Π½ΠΈΡ€ΠΎΠ²Π°Π½ΠΈΠ΅ экспСримСнтов, ΠΈΡ… Π½Π°ΡƒΡ‡Π½Ρ‹ΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΈ ΡΡ‚Π°Ρ‚ΠΈΡΡ‚ΠΈΡ‡Π΅ΡΠΊΡƒΡŽ ΠΎΠ±Ρ€Π°Π±ΠΎΡ‚ΠΊΡƒ ΠΏΠΎΠ»ΡƒΡ‡Π΅Π½Π½Ρ‹Ρ… Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚ΠΎΠ², ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Π΅ прСдставил Π² ΡΡ‚Π°Ρ‚ΡŒΡΡ… ΠΈ Π΄ΠΎΠΊΠ»Π°Π΄Π°Ρ… Π½Π° ΠΊΠΎΠ½Ρ„СрСнциях. Π’ Ρ…ΠΎΠ΄Π΅ выполнСния диссСртационной Ρ€Π°Π±ΠΎΡ‚Ρ‹ Π°Π²Ρ‚ΠΎΡ€ ΠΎΠ²Π»Π°Π΄Π΅Π» соврСмСнной Ρ‚Π΅Ρ…Π½ΠΎΠ»ΠΎΠ³ΠΈΠ΅ΠΉ получСния трансгСнных ΠΆΠΈΠ²ΠΎΡ‚Π½Ρ‹Ρ…, ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠΌ ΠΌΠΈΠΊΡ€ΠΎΠΈΠ½ΡŠΠ΅ΠΊΡ†ΠΈΠΈ Ρ€Π΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½Ρ‚Π½ΠΎΠΉ Π”ΠΠš Π² ΠΌΡƒΠΆΡΠΊΠΎΠΉ пронуклСус Π·ΠΈΠ³ΠΎΡ‚, ΠΌΠ΅Ρ‚ΠΎΠ΄Π°ΠΌΠΈ ΠΊΡƒΠ»ΡŒΡ‚ΠΈΠ²ΠΈΡ€ΠΎΠ²Π°Π½ΠΈΡ эмбрионов, Π° Ρ‚Π°ΠΊΠΆΠ΅ ΠΏΡ€Π΅Π΄Π»ΠΎΠΆΠΈΠ» ряд ΠΎΡ€ΠΈΠ³ΠΈΠ½Π°Π»ΡŒΠ½Ρ‹Ρ…, практичСски Π·Π½Π°Ρ‡ΠΈΠΌΡ‹Ρ… ΡƒΡΠΎΠ²Π΅Ρ€ΡˆΠ΅Π½ΡΡ‚Π²ΠΎΠ²Π°Π½ΠΈΠΉ Π² Ρ‚Π΅Ρ…Π½ΠΎΠ»ΠΎΠ³ΠΈΡŽ вымывания ΠΈ Ρ‚рансплантации эмбрионов ΠΆΠΈΠ²ΠΎΡ‚Π½Ρ‹Ρ…. БоискатСлСм созданы ΡƒΠ½ΠΈΠΊΠ°Π»ΡŒΠ½Ρ‹Π΅ Π»ΠΈΠ½ΠΈΠΈ трансгСнных ΠΌΡ‹ΡˆΠ΅ΠΉ, позволившиС ΠΈΠ·ΡƒΡ‡ΠΈΡ‚ΡŒ Ρ…Π°Ρ€Π°ΠΊΡ‚Π΅Ρ€ ΠΏΠ΅Ρ€Π΅Π΄Π°Ρ‡ΠΈ трансгСна ΠΈ ΡƒΡΠ»ΠΎΠ²ΠΈΡ, ΠΎΠ±Π΅ΡΠΏΠ΅Ρ‡ΠΈΠ²Π°ΡŽΡ‰ΠΈΠ΅ Π²Ρ‹ΡΠΎΠΊΡƒΡŽ ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ†ΠΈΡŽ Ρ€Π΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½Ρ‚Π½ΠΎΠ³ΠΎ Π»Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½Π° Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° с ΠΌΠΎΠ»ΠΎΠΊΠΎΠΌ трансгСнных ΠΆΠΈΠ²ΠΎΡ‚Π½Ρ‹Ρ…, ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Π΅ Π΄Π΅ΠΏΠΎΠ½ΠΈΡ€ΠΎΠ²Π°Π½Ρ‹ Π² «Π’рансгСнбанкС» Π˜Π‘Π“ РАН.

ΠžΠ±ΡŠΡ‘ΠΌ ΠΈ ΡΡ‚Ρ€ΡƒΠΊΡ‚ΡƒΡ€Π° диссСртации.

ДиссСртация ΠΈΠ·Π»ΠΎΠΆΠ΅Π½Π° Π½Π° 121 страницС, состоит ΠΈΠ· ΡΠ»Π΅Π΄ΡƒΡŽΡ‰ΠΈΡ… Ρ€Π°Π·Π΄Π΅Π»ΠΎΠ²: Π²Π²Π΅Π΄Π΅Π½ΠΈΠ΅, ΠΎΠ±Π·ΠΎΡ€ Π»ΠΈΡ‚Π΅Ρ€Π°Ρ‚ΡƒΡ€Ρ‹, ΠΌΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Ρ‹ ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹, Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ ΠΈ ΠΈΡ… ΠΎΠ±ΡΡƒΠΆΠ΄Π΅Π½ΠΈΠ΅, Π²Ρ‹Π²ΠΎΠ΄Ρ‹, список Π»ΠΈΡ‚Π΅Ρ€Π°Ρ‚ΡƒΡ€Ρ‹ (228 источников). Π Π°Π±ΠΎΡ‚Π° содСрТит 8 Ρ‚Π°Π±Π»ΠΈΡ† ΠΈ 31 рисунок.

Π’Ρ‹Π²ΠΎΠ΄Ρ‹.

1. Π’Ρ‹Π±Ρ€Π°Π½Π° ΠΎΠΏΡ‚ΠΈΠΌΠ°Π»ΡŒΠ½Π°Ρ ΠΈΠ· 9 исслСдованных гСнная конструкция, ΠΎΠ±Π΅ΡΠΏΠ΅Ρ‡ΠΈΠ²Π°ΡŽΡ‰Π°Ρ Π½Π°ΠΈΠ±ΠΎΠ»ΡŒΡˆΡƒΡŽ (Π² ΡΡ€Π΅Π΄Π½Π΅ΠΌ 16,7 Π³/Π» ΠΈ ΠΌΠ°ΠΊΡΠΈΠΌΡƒΠΌ 160,0 Π³/Π») ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ†ΠΈΡŽ Ρ€Π΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½Ρ‚Π½ΠΎΠ³ΠΎ Π»Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½Π° Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° с ΠΌΠΎΠ»ΠΎΠΊΠΎΠΌ трансгСнных ΠΌΡ‹ΡˆΠ΅ΠΉ — LTF5. Она состоит ΠΈΠ· Π³Π΅Π½ΠΎΠΌΠ½ΠΎΠΉ ΠΊΠΎΠΏΠΈΠΈ Π³Π΅Π½Π° Π»Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½Π° Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° ΠΈ Π½Π°Ρ…одится ΠΏΠΎΠ΄ ΠΊΠΎΠ½Ρ‚Ρ€ΠΎΠ»Π΅ΠΌ (3-ΠΊΠ°Π·Π΅ΠΈΠ½ΠΎΠ²ΠΎΠ³ΠΎ ΠΏΡ€ΠΎΠΌΠΎΡ‚ΠΎΡ€Π°, инсуляторов кластСра Π -Π³Π»ΠΎΠ±ΠΈΠ½ΠΎΠ²Ρ‹Ρ… Π³Π΅Π½ΠΎΠ² ΠΊΡƒΡ€.

2. ΠŸΡ€ΠΎΡΠ»Π΅ΠΆΠ΅Π½Π° ΠΏΠ΅Ρ€Π΅Π΄Π°Ρ‡Π° трансгСна Π² Ρ€ΡΠ΄Ρƒ 8-ΠΌΠΈ ΠΏΠΎΠΊΠΎΠ»Π΅Π½ΠΈΠΉ 3885 ΠΏΠΎΡ‚ΠΎΠΌΠΊΠΎΠ² 67 ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½Ρ‹Ρ… трансгСнных ΠΌΡ‹ΡˆΠ΅ΠΉ. ΠšΠΎΠ»ΠΈΡ‡Π΅ΡΡ‚Π²ΠΎ трансгСнных ΠΏΠΎΡ‚ΠΎΠΌΠΊΠΎΠ² Π² 1-ΠΎΠΌ ΠΏΠΎΠΊΠΎΠ»Π΅Π½ΠΈΠΈ колСбалось ΠΎΡ‚ 3,4% (линия LTF6 728) Π΄ΠΎ 85,7% (линия LTF5 146), Π²ΠΎ 2-ΠΎΠΌ ΠΈ ΠΏΠΎΡΠ»Π΅Π΄ΡƒΡŽΡ‰ΠΈΡ… поколСниях срСдний ΡƒΡ€ΠΎΠ²Π΅Π½ΡŒ ΠΏΠ΅Ρ€Π΅Π΄Π°Ρ‡ΠΈ трансгСна потомству приблиТался ΠΊ 50% ΠΈ Π΅Π³ΠΎ колСбания ΡƒΠΌΠ΅Π½ΡŒΡˆΠΈΠ»ΠΈΡΡŒ.

3. УстановлСно, Ρ‡Ρ‚ΠΎ продукция Ρ€Π΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½Ρ‚Π½ΠΎΠ³ΠΎ Π»Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½Π° Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° тканСспСцифична ΠΈ Ρ 4 ΠΏΠΎ 17 дСнь Π»Π°ΠΊΡ‚Π°Ρ†ΠΈΠΈ остаётся ΡΡ‚Π°Π±ΠΈΠ»ΡŒΠ½ΠΎΠΉ, Π½Π°Ρ…ΠΎΠ΄ΡΡΡŒ Π½Π° ΡƒΡ€ΠΎΠ²Π½Π΅ срСднСго для ΠΌΡ‹ΡˆΠΈ Π² Ρ€Π°Π·Π½Ρ‹Π΅ Π΄Π½ΠΈ Π»Π°ΠΊΡ‚Π°Ρ†ΠΈΠΈ.

4. УстановлСно, Ρ‡Ρ‚ΠΎ Ρ€Π΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½Ρ‚Π½Ρ‹ΠΉ Π»Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½ Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ°, Π²Ρ‹Π΄Π΅Π»Π΅Π½Π½Ρ‹ΠΉ ΠΈΠ· ΠΌΠΎΠ»ΠΎΠΊΠ° трансгСнных ΠΌΡ‹ΡˆΠ΅ΠΉ, Π°Π½Π°Π»ΠΎΠ³ΠΈΡ‡Π΅Π½ Π»Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½Ρƒ ΠΌΠΎΠ»ΠΎΡ‡Π½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ‹ ΠΆΠ΅Π½Ρ‰ΠΈΠ½ ΠΏΠΎ Ρ„ΠΈΠ·ΠΈΠΊΠΎ-химичСским ΠΈ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡ‡Π΅ΡΠΊΠΈΠΌ свойствамнСкотороС ΠΎΡ‚Π»ΠΈΡ‡ΠΈΠ΅ состоит Π² ΡƒΡ€ΠΎΠ²Π½Π΅ гликозилирования Ρ€Π΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½Ρ‚Π½ΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ°.

5. ΠžΠΏΡ€Π΅Π΄Π΅Π»Π΅Π½ΠΎ, Ρ‡Ρ‚ΠΎ трансгСн Π»Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½Π° Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° Π½Π΅ Π²Π»ΠΈΡΠ΅Ρ‚ Π½Π° ΡΠΎΡΡ‚ояниС Π·Π΄ΠΎΡ€ΠΎΠ²ΡŒΡ ΠΈ Ρ€Π΅ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ‚ΠΈΠ²Π½ΡƒΡŽ ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡ‚ΡŒ трансгСнных ΠΌΡ‹ΡˆΠ΅ΠΉ.

6. Показана ΠΏΠ΅Ρ€ΡΠΏΠ΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ использования исслСдованных гСнСтичСских конструкций для получСния трансгСнных ΡΠ΅Π»ΡŒΡΠΊΠΎΡ…ΠΎΠ·ΡΠΉΡΡ‚Π²Π΅Π½Π½Ρ‹Ρ… ΠΆΠΈΠ²ΠΎΡ‚Π½Ρ‹Ρ… — ΠΏΡ€ΠΎΠ΄ΡƒΡ†Π΅Π½Ρ‚ΠΎΠ² Ρ€Π΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½Ρ‚Π½ΠΎΠ³ΠΎ Π»Π°ΠΊΡ‚ΠΎΡ„Π΅Ρ€Ρ€ΠΈΠ½Π° Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ° с ΠΌΠΎΠ»ΠΎΠΊΠΎΠΌ.

ΠŸΠΎΠΊΠ°Π·Π°Ρ‚ΡŒ вСсь тСкст

Бписок Π»ΠΈΡ‚Π΅Ρ€Π°Ρ‚ΡƒΡ€Ρ‹

  1. Cohen SN, Chang AC, Boyer HW, Helling RB, (1973). Construction of biologically functional bacterial plasmids in vitro. Proc Natl Acad Sci USA 70: 3240−3244
  2. Jaenisch R, Fan H, Croker B. (1975) Infection of preimplantation mouse embryos and of newborn mice with leukemia virus: tissue distribution of viral DNAandRNAand leukemogenesis in the adult animal Proc Natl Acad Sci USA 72: 4008−4012.
  3. Waterston RH, Lindblad-Toh K, Bimey E, Rogers J, Abril JF, Agarwal P, et al. (2002). Initial sequencing and comparative analysis of the mouse genome. Nature 420: 520 562
  4. Hammer RE, Pursel VG, Rexroad CE, Jr., Wall RJ, Bolt DJ, Ebert KM, et al. (1985). Production of transgenic rabbits, sheep and pigs by microinjection. Nature 315: 680−683.
  5. Willadsen SM, (1986). Nuclear transplantation in sheep embryos. Nature 320: 63−65.
  6. Krimpenfort P, Rademakers A, Eyestone W, van der Schans A, van den Broek S, Kooiman P, et al. (1991). Generation of transgenic dairy cattle using 'in vitro' embryo production. Biotechnology (NY) 9: 844−847.
  7. Wright G, Carver A, Cottom D, Reeves D, Scot A, Simons P, et al. (1991). High level expression of active human alpha-1-antitrypsin in the milk of transgenic sheep. Biotechnology (NY) 9: 830−834.
  8. Muller M, Brenig B, Winnacker EL, Brem G, (1992). Transgenic pigs carrying cDNA copies encoding the murine Mxl protein which confers resistance to influenza virus infection. Gene 121: 263−270.
  9. Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KH, (1997). Viable offspring derived from fetal and adult mammalian cells. Nature 385: 810−813.
  10. Petters RM, Alexander CA, Wells KD, Collins EB, Sommer JR, Blanton MR, et al. (1997). Genetically engineered large animal model for studying cone photoreceptor survival and degeneration in retinitis pigmentosa. Nat Biotechnol 15: 965—970.
  11. Cibelli JB, Stice SL, Golueke PJ, Kane JJ, Jerry J, Blackwell C, et al. (1998). Cloned transgenic calves produced from nonquiescent fetal fibroblasts. Science 280: 12 561 258.
  12. McCreath KJ, Howcroft J, Campbell KH, Colman A, Schnieke AE, Kind AJ, (2000). Production of gene-targeted sheep by nuclear transfer from cultured somatic cells. Nature 405: 1066−1069.
  13. Lazaris A, Arcidiacono S, Huang Y, Zhou JF, Duguay F, Chretien N, et al. (2002). Spider silk fibers spun from soluble recombinant silk produced in mammalian cells. Science 295: 472—476.
  14. Kuroiwa Y, Kasinathan P, Matsushita H, Sathiyaselan J, Sullivan EJ, Kakitani M, et al. (2004). Sequential targeting of the genes encoding immunoglobulin- mu and prion protein in cattle. Nat Genet 36: 775−780.
  15. Brophy B, Smolenski G, Wheeler T, Wells D, L’Huillier P, Laible G, (2003). Cloned transgenic cattle produce milk with higher levels of beta-casein and kappa-casein. Nat Biotechnol 21: 157−162.
  16. Phelps CJ, Koike C, Vaught TD, Boone J, Wells KD, Chen SH, et al. (2003). Production of alpha 1,3-galactosyltransferase-deficient pigs. Science 299: 411—414.
  17. Wall RJ, Powell AM, Paape MJ, Kerr DE, Bannerman DD, Pursel VG, (2005). Genetically enhanced cows resist intramammary Staphylococcus aureus infection. Nat Biotechnol 23: 445151.
  18. Polejaeva IA, Campbell KH, (2000). New advances in somatic cell nuclear transfer: application in transgenesis. Theriogenology 53: 117−126.
  19. Chan AW, Homan EJ, Ballou LU, Burns JC, Bremel RD, (1998). Transgenic cattle produced by reverse-transcribed gene transfer in oocytes. Proc Natl Acad Sci USA 95: 14 028−14 033.
  20. Clark J, Whitelaw B, (2003). A future for transgenic livestock. Nat Rev Genet. C) ct-4(10):825−33.
  21. Brackett BG, Baranska W, Sawicki W, Koprowski H, (1971) Uptake of heterologous genome by mammalian spermatozoa and its transfer to ova through fertilization. Proc Natl Acad Sci USA 68: 353−357.
  22. Maione B, Lavitrano M, Spadafora C, Kiessling AA, (1998). Sperm-mediated gene transfer in mice. Mol Reprod Dev 50: 406—409.
  23. Rieth A, Pothier F, Sirard MA, (2000). Electroporation of bovine spermatozoa to carry DNA containing highly repetitive sequences into oocytes and detection of homologous recombination events. Molecular Reproduction and Development 57: 338—345.
  24. Celebi C, Guillaudeux T, Auvray P, Vallet- Erdtmann V, Jegou B,(2003). The Making of «Transgenic Spermatozoa». Biol Reprod 68: 1477—1483.
  25. Nagano M, Brinster Π‘ J, Orwig KE, Ryu BY, Avarbock MR, Brinster RL, (2001). Transgenic mice produced by retroviral transduction of male germ-line stem cells. Proc Natl Acad Sci USA 98: 13 090−13 095.
  26. Honaramooz A, Megee SO, Dobrinski I, (2002). Germ cell transplantation in pigs. Biol Reprod 66: 21−28.
  27. Honaramooz A, Behboodi E, Blash S, Megee SO, Dobrinski I, (2003). Germ cell transplantation in goats. Mol Reprod Dev 64: 422−428.
  28. Robertson E, Bradley A, Kuehn M, Evans M, (1986). Germ-line transmission of genes introduced into cultured pluripotential cells by retroviral vector. Nature 323: 445—448.
  29. Evans MJ, Kaufman MH, (1981). Establishment in culture of pluripotential cells from mouse embryos. Nature 292: 154−156.
  30. Martin GR, (1981). Isolation of a pluripotent cell line from early mouse embryos cultured in medium condiyioned by teratocarcinoma stem cells. Proc Natl Acad Sci USA 78: 7634—7638.
  31. Gorodetsky, S.I., Bremel, R. The factors of tissue-specific expression of the bovine b-casein gene.(1998) In Mammary Gland Transgenesis. Therapeutic Protein Production.ed. F.O.Castro, and J. Janne, Springer, 19−40.
  32. Gorodetsky, S.I., and Bremel, R.D. (1996) Post-transcriptional regulation of bovine b-casein gene expression. Posttranscriptional RNA processing. Keystone Symposia, 28,308.
  33. Shim H, Gutierrez-Adan A, Chen LR, BonDurant RH, Behboodi E, Anderson GB, (1997). Isolation of pluripotent stem cells from cultured porcine primordial germ cells. Biol Reprod 57: 1089−1095.
  34. Saito S, Sawai K, Ugai H, Moriyasu S, Minamihashi A, Yamamoto Y, et al. (2003). Generation of cloned calves and transgenic chimeric embryos from bovine embryonic stemlike cells. Biochem Biophys Res Commun 309: 104—113.
  35. Gordon JW, Ruddle FH, (1981). Integration and stable germ line transmission of genes injected into mouse pronuclei. Science 214: 1244—1246.
  36. Palmiter RD, Brinster RL, Hammer RE, Trumbauer ME, Rosenfeld MG, Birnberg NC, Evans RM, (1982). Dramatic growth of mice that develop from eggs micro injected with metallothionein-growth hormone fusion genes. Nature 300: 611—615.
  37. Nottle MB, Haskard KA, Verma PJ, Du ZT, Grupen CG, Mcllfatrick SM, et al. (2001). Effect of DNA concentration on transgenesis rates in mice and pigs. Transgenic Res 10: 523−531.
  38. Keefer CL,(2004). Production of bioproducts through the use of transgenic animal models. Anim Reprod Sci 82−83: 5−12.
  39. Seidel GE, Jr., (1993). Resource requirements for transgenic livestock research. J Anim Sci 71: 26−33.
  40. Kasinathan P, Knott JG, Moreira PN, Burnside AS, Jerry DJ, RobI JM, (2001). Effect of fibroblast donor cell age and cell cycle on development of bovine nuclear transfer embryos in vitro. Biol Reprod 64: 1487−1493.
  41. Iguma LT, Lisauskas SF, Melo EO, Franco MM, Pivato I, Vianna GR, et al. (2005). Development of bovine embryos reconstructed by nuclear transfer of transfected and non-transfected adult fibroblast cells. Genet Mol Res 4: 55−66.
  42. Melo EO, Sousa RV, Iguma LT, Franco MM, Rech EL, Rumpf R, (2005). Isolation of transfected fibroblast clones for use in nuclear transfer and transgene detection in cattle embryos. Genet Mol Res 4: 812−821.
  43. Sikes ML, O’Malley BW, Jr., Finegold MJ, Ledley FD, (1994). In vivo gene transfer into rabbit thyroid follicular cells by direct DNA injection. Hum Gene Ther 5: 837— 844.
  44. Williams RS, Johnston SA, Riedy M, DeVit MJ, McElligott SG, Sanford JC, (1991). Introduction of foreign genes into tissues of living mice by DNA-coated microprojectiles. Proc Natl Acad Sci USA 88: 2726−2730.
  45. Grosjean F, Bertschinger M, Hacker DL, Wurm FM. (2006) Multiple glycerol shocks increase the calcium phosphate transfection of non-synchronized CHO cells. Biotechnol Lett. Nov-28(22): 1827−33. Epub 2006 Sep 29.
  46. Kovesdi I, Brough DE, Bruder JT, Wickham TJ, (1997). Adenoviral vectors for gene transfer. Curr Opin Biotechnol 8: 583−589.
  47. Caplen NJ, Kinrade E, Sorgi F, Gao X, Gruenert D, Geddes D, et al. (1995) In vitro liposome-mediated DNA transfection of epithelial cell lines using the cationic liposome DC-Chol/DOPE. Gene Ther 2: 603−613.
  48. Oliveira RR, Carvalho DM, Lisauskas S, Mello E, Vianna GR, Dode MA, et al. (2005). Effectiveness of liposomes to transfect livestock fibroblasts. Genet Mol Res 4: 185 196.
  49. Schnieke AE, Kind AJ, Ritchie WA, Mycock K, Scott AR, Ritchie M, Wilmut I, et al. (1997). Human factor IX transgenic sheep produced by transfer of nuclei from transfected fetal fibroblasts. Science 278: 2130−2133.
  50. Kues WA, Niemann H, (2004). The contribution of farm animals to human health. Trends Biotechnol 22: 286−294.
  51. Kasinathan P, Knott JG, Wang Z, Jerry DJ, Robl JM, (2001b). Production of calves from G1 fibroblasts. Nat Biotechnol 19: 1176−1178.
  52. Gibbons J, Arat S, Rzucidlo J, Miyoshi K, Waltenburg R, Respess D, et al. (2002). Enhanced survivability of cloned calves derived from roscovitine-treated adult somatic cells. Biol Reprod 66: 895−900.
  53. Sullivan EJ, Kasinathan S, Kasinathan P, Robl JM, Collas P, (2004). Cloned calves from chromatin remodeled in vitro. Biol Reprod 70: 146−153.
  54. Wall RJ, Kerr DE, Bondioli KR, (1997). Transgenic dairy cattle: genetic engineering on a large scale. J Dairy Sci 80: 2213−2224.
  55. Miller HI, (2002). As biotech turns 20. Nat Rev Drug Discov 1: 1007−1008.
  56. Dyck MK, Lacroix D, Pothier F, Sirard MA, (2003). Making recombinant proteins in animals different systems, different applications. Trends Biotechnol 21: 394−399.
  57. Zbikowska HM, Soukhareva N, Behnam R, Chang R, Drews R, Lubon H, et al. (2002). The use of the uromodulin promoter to target production of recombinant proteins into urine of transgenic animals. Transgenic Res 11: 425−435.
  58. Zbikowska HM, Soukhareva N, Behnam R, Lubon H, Hammond D, Soukharev S, (2002). Uromodulin promoter directs high-level expression of biologically active human alphal- antitrypsin into mouse urine. Biochem J 365: 7−11.
  59. Velander WH, Johnson JL, Page RL, Russell CG, Subramanian A, Wilkins TD, et al. (1992). High-level expression of a heterologous protein in the milk of transgenic swine using the cDNA encoding human protein C. Proe Natl Acad Sci USA 89: 12 003−12 007.
  60. Van Berkel PH, Welling MM, Geerts M, van Veen HA, Ravensbergen B, Salaheddine M, et al. (2002). Large scale production of recombinant human laetoferrin in the milk of transgenic cows. Nat Biotechnol 20: 484−487.
  61. Rudolph NS, (1999). Biopharmaceutical production in transgenic livestock. Trends Biotechnol 17: 367−374.
  62. Lipinski D, Jura J, Kalak R, Plawski A, Kala M, Szalata M, et al. (2003). Transgenic rabbit producing human growth hormone in milk. J Appl Genet 44: 165—174.
  63. Michalak E, Lipinski D, Slomski R, (2006). Loop formation by the transgene WAP: 6 x ITishGH in transgenic rabbit fibroblast, revealed by fluorescence in situ hybridization to nuclear halos. J Appl Genet 47: 247−249.
  64. J. (2009)First US approval for a transgenic animal drug. Nat Biotechnol. Apr-27(4):302−4.
  65. Massoud M, Attal J, Thepot D, Pointu H, Stinnakre MG, Theron MC, et al. (1996). The deleterious effects of human erythropoietin gene driven by the rabbit whey acidic protein gene promoter in transgenic rabbits. Reprod Nutr Dev 36: 555−563.
  66. Ebert KM, DiTullio P, Barry CA, Schindler JE, Ayres SL, Smith Π’Π•, et al. (1994). Induction of human tissue plasminogen activator in the mammary gland of transgenic goats. Biotechnology (NY) 12: 699−702.
  67. Niemann H, Halter R, Carnwath JW, Herrmann D, Lemme E, Paul D, (1999). Expression of human blood clotting factor VIII in the mammary gland of transgenic sheep. Transgenic Res 8: 237−247.
  68. Karatzas CN, (2003). Designer milk from transgenic clones. Nat Biotechnol 21: 138−139.
  69. Karatzas CN, Turner JD, (1997). Toward altering milk composition by genetic manipulation: current status and challenges. J Dairy Sci 80: 2225−2232.
  70. Kang Y, Jimenez-Flores R, Richardson T, (1986). Casein genes and genctic engineering of the caseins. Basic Life Sci 37: 95−111.
  71. Stacey A, Schnieke A, Kerr M, Scott A, McKee C, Cottingham I, et al. (1995). Lactation is disrupted by alpha-lactalbumin deficiency and can be restored by human alpha-lactalbumin gene replacement in mice. Proc Natl Acad Sci USA 92: 2835−2839.
  72. Jost B, Vilotte JL, Duluc I, Rodeau JL, Freund JN, (1999). Production of low-lactose milk by ectopic expression of intestinal lactase in the mouse mammary gland. Nat Biotechnol 17: 160−164.
  73. Wheeler MB, (2003). Production of transgenic livestock: promise fulfilled. J Anim Sci 81: 32−37.
  74. Soukka T, Tenovuo J, Lenander-Lumikari M, (1992). Fungicidal effect of human lactoferrin against Candida albicans. FEMS Microbiol Lett 69: 223−228.
  75. Hasegawa K, Motsuchi W, Tanaka S, Dosako S, (1994). Inhibition with lactoferrin of in nitro infection with human herpes virus. Jpn J Med Sci Biol 47: 73−85.
  76. Nuijens JH, van Berkel PH, Geerts ME, Hartevelt PP, de Boer HA, van Veen HA, Pieper FR, (1997). Characterization of recombinant human lactoferrin secreted in milk of transgenic mice. J Biol Chem 272: 8802−8807.
  77. Platenburg G.J., Kootwijk E.P., Kooiman P.M., Woloshuk S.L., Nuijens J.H., Krimpenfort P.J., Pieper F.R., de Boer H.A., Strijker R., (1994) Expression of human lactoferrin in milk of transgenic mice, Transgenic research 3: 99−108.
  78. Kim S.J., Lee К., Yu D., Han Y., Lee C., Nam M., Moon H., Lee K., Expression Analysis of a Bovine P-Casein/Human Lactoferrin Hybrid Gene in Transgenic Mice, The Journal of reproduction and development 43 (1997) 143−149
  79. Liu Z., Zhao C., Fan Π’., Dai Y., Zhao Z., Wang L., Zheng M., Feng J., Chen Y., Duan Y., Li N., (2004) Variable expression of human lactoferrin gene in mice milk driven by its 90 KB upstream flanking sequences, Animal biotechnology 15: 21−31.
  80. Shi G, Chen H, Wu X, Zhou Y, Liu Z, Zheng T, Huang P. (2009) A mWAP-hLF hybrid gene locus gave extremely high level expression of human lactoferrin in the milk of transgenic mice. Transgenic Res. 2009 Aug-18(4):573−82.
  81. Zhang J, Li L, Cai Y, Xu X, Chen J, Wu Y, Yu H, Yu G, Liu S, Zhang A, Chen J, Cheng G. (2008) Expression of active recombinant human lactoferrin in the milk of transgenic goats. Protein Expr Purif. Feb-57(2): 127−35. Epub 2007 Nov 20.
  82. Li L., Shen W., Min L., Dong H., Sun Y., Pan Q., (2006)Human lactoferrin transgenic rabbits produced efficiently using dimethylsulfoxide-sperm-mediated gene transfer, Reproduction, fertility, and development 18: 689−695.
  83. Kerr DE, Wellnitz O, (2003). Mammary expression of new genes to combat mastitis. J Anim Sci 81: 3847.
  84. Kerr DE, Plaut K, Branley AJ, Williamson CM, Lax AJ, Moore K, et al. (2001). Lysostaphin expression in mammary glands confers protection against staphylococcal infection in transgenic mice. Nat Biotechnol 19: 66−70.
  85. Detwiler LA, Rubenstein R, (2000). Bovine spongiform encephalopathy: an overview. Asaio J 46: S73—79.
  86. Weissmann C, Enari M, Klohn PC, Rossi D, Flechsing E, (2002). Transmission of prions. Proc Natl Acad Sci USA 99: 16 378−16 383.
  87. Bueler H, Fischer M, Lang Y, Bluethmann H, Lipp HP, DeArmond SJ, et al. (1992). Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 356: 577−582.
  88. Bueler H, Aguzzi A, Sailer A, Greiner RA, Autenried P, Aguet M, Weissmann C, (1993). Mice devoid of PrP are resistant to scrapie. Cell 73: 1339−1347.
  89. Oria R., Alvarez-Hernandez X., Liceaga J. and Brock J. H. (1988) Uptake and handling of iron from transferrin, lactoferrin and immune complexes by a macrophage cell line. Biochem. J. 252: 221−225
  90. Denning C, Burl S, Ainslie A, Bracken J, Dinnyes A, Fletcher J, et al. (2001). Deletion of the alpha (1,3) galactosyl transferase (GGTA1) gene and the prion protein (PrP) gene in sheep. Nat Biotechnol 19: 559−562.
  91. Barthel R, Feng J, Piedrahita JA, McMurray DN, Templeton JW, Adams LG, 2001) Stable transfection of the bovine NRAMP1 gene into murine RAW264.7 cells: effect on Brucella abortus survival. Infect Immun 69: 3110—3119.
  92. Pursel VG, Pinkert CA, Miller KF, Bolt DJ, Campbell RG, Palmiter RD, 1989. Genetic engineering of livestock. Science 244: 1281—1288.
  93. Grobet L, Martin LJ, Poncelet D, Pirottin D, Brouwers B, Riquet J, et al. (1997). A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nat Genet 17: 71−74.
  94. McPherron AC, Lee SJ, (1997). Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA 94: 12 457−12 461.
  95. McPherron AC, Lawler AM, Lee SJ, (1997). Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387: 83—90.
  96. Souza T, MacDougall C, Campbell BK, McNeilly AS, Baird DT, (2001). The Booroola (FecB) phenotype is associated with a mutation in the bone morphogenetic receptor type 1 Π’ (BMPR1B) gene. J Endocrinol 169: Rl-6.
  97. Juengel JL, Hudson NL, Heath DA, Smith P, Reader KL, Lawrence SB, et al.2002). Growth differentiation factor 9 and bone morphogenetic protein 15 are essential for ovarian follicular development in sheep. Biol Reprod 67: 1777—1789
  98. Powell Π’Π‘, Walker SK, Bawden CS, Sivaprasad AV, Rogers GE, (1994). Transgenic sheep and wool growth: possibilities and current status. Reprod Fertil Dev 6: 615−623.
  99. Auchincloss H, Jr., Sachs DH, (1998) Xenogeneic transplantation. Annu Rev Immunol 16: 433470.
  100. Diamond LE, Quinn CM, Martin MJ, Lawson J, Piatt JL, Logan JS, (2001). A human CD46 transgenic pig model system for the study of discordant xenotransplantation. Transplantation 71: 132−142.
  101. Zaidi A, Schmoeckel M, Bhatti F, Waterworth P, Tolan M, Cozzi E, et al. (1998). Life-supporting pig-to-primate renal xenotransplantation using genetically modified donors. Transplantation 65: 1584−1590.
  102. Zawada WM, Cibelli JB, Choi PK, Clarkson ED, Golueke PJ, Witta SE, et al.1998). Somatic cell cloned transgenic bovine neurons for transplantation in parkinsonian rats. Nat Med 4: 569−574.
  103. Imaizumi T, Lankford KL, Burton WV, Fodor WL, Kocsis JD, (2000). Xenotransplantation of transgenic pig olfactory ensheathing cells promotes axonal regeneration in rat spinal cord. Nat Biotechnol 18: 949—953.
  104. Patience C, Takeuchi Y, Weiss RA, (1997). Infection of human cells by an endogenous retrovirus of pigs. Nat Med 3: 282−286.
  105. Patience C, Patton GS, Takeuchi Y, Weiss RA, McClure MO, Rydberg L, Breimer ME, (1998). No evidence of pig DNA or retroviral infection in patients with short-term extracorporeal connection to pig kidneys. Lancet 352: 699−701.
  106. Paradis K, Langford G, Long Z, Heneine W, Sandstrom P, Switzer WM, et al.1999). Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. The XEN 111 Study Group. Science 285: 1236−1241.
  107. Wobus AM, Boheler KR, (2005). Embryonic stem cells: prospects for developmental biology and cell therapy. Physiol Rev 85: 635−678.
  108. International Human Genome Sequencing Consortium, (2004). Finishing the euchromatic sequence of the human genome. Nature 431: 931−945.
  109. Marx J, (2003). Medicine. Building better mouse models for studying cancer. Science 299: 1972−1975.
  110. Draghia-Akli R, Fiorotto ML, Hill LA, Malone PB, Deaver DR, Schwartz RJ, (1999). Myogenic expression of an injectable protease-resistant growth hormone- releasing hormone augments long-term growth in pigs. Nat Biotechnol 17: 1179−1183.
  111. Djojosubroto MW, Choi YS, Lee HW, Rudolph KL, (2003). Telomeres and telomerase in aging, regeneration and cancer. Mol Cells 15: 164−175.
  112. Mogford JE, Liu WR, Reid R, Chiu CP, Said H, Chen SJ, et al. (2006). Adenoviral human telomerase reverse transcriptase dramatically improves ischemic wound healing without detrimental immune response in an aged rabbit model. Hum Gene Ther 17: 651−660.
  113. Rudolph KL, Millard M, Bosenberg MW, DePinho RA, (2001). Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat Genet 28: 155— 159.
  114. Cawthon RM, Smith KR, O’Brien E, Sivatchenko A, Kerber RA, (2003). Association between telomere length in blood and mortality in people aged 60 years or older. Lancet 361: 393−395.
  115. Shicls PG, Kind AJ, Campbell KH, Waddington D, Wilmut I, Colman A, Schnieke AE, (1999). Analysis of telomere lengths in cloned sheep. Nature 399: 316−317.
  116. Lanza RP, Cibelli JB, Blackwell C, Cristofalo VJ, Francis MK, Baerlocher GM, et al. (2000). Extension of cell life-span and telomere length in animals cloned from senescent somatic cells. Science 288: 665−669.
  117. Wakayama T, Shinkai Y, Tamashiro KL, Niida H, Blanchard DC, Blanchard RJ, et al. (2000). Cloning of mice to six generations. Nature 407: 318−319.
  118. Betts D, Bordignon V, Hill J, Winger Q, Westhusin M, Smith L, King W, (2001) Reprogramming of telomerase activity and rebuilding of telomere length in cloned cattle. Proc Natl Acad Sci USA 98: 1077−1082.
  119. Suda O, Smith LA, d’Uscio LV, Peterson Π’Π•, Katusic ZS, (2005). In vivo expression of recombinant vascular endothelial growth factor in rabbit carotid artery increases production of superoxide anion. Arterioscler Thromb Vase Biol 25: 506−511.
  120. Metz-Boutigue M. H., Jolles J., Mazurier J., Schoentgen F., Legrand D., Spik G. et al. (1984) Human lactotransferrin: amino acid sequence and structural comparisons with other transferrins. Eur. J. Biochem. 145: 659−676
  121. Woodbury RG, Brown JP, Yeh MY, Hellstrom I, Hellstrom KE (1980) Identification of a cell surface protein, p97, in human melanomas and certain other neoplasms. Proc Natl Acad Sci USA 77:2183−2187
  122. Anderson B. F., Baker H. M., Norris G. E., Rice D. W. and Baker E. N. (1989) Structure of human lactoferrin: crystallographic structure analysis and refi nement at 2.8 A resolution. J. Mol. Biol. 209: 711−734
  123. Baker H. M., Anderson B. F. and Baker E. N. (2003) Dealing with iron: common structural principles in proteins that transport iron and heme. Proc. Natl. Acad. Sci. USA 100: 3579−3583
  124. Ward P. P., Mendoza-Meneses M., Mulac-Jericevic Π’., Cunningham G. A., Saucedo-Cardenas O., Teng Π‘. T. et al. (1999) Restricted spatiotemporal expression of lactoferrin during murine embryonic development. Endocrinology 140: 1852—1860
  125. Π‘. Π’., Beard C. and Gladwell W. (2002) Differential expression and estrogen response of lactoferrin gene in the female reproductive tract of mouse, rat and hamster. Biol. Reprod. 67: 1439−1449
  126. Masson P. L., Heremans J. F. and Schonne E. (1969) Lactoferrin, an iron-binding protein in neutrophilic leukocytes. J. Exp. Med. 130: 643−658
  127. Montreuil J., Tonnelat J. and Mullet S. (1960) Preparation et proprietes de la lactosiderophiline (lactotransferrine) du lait de femme. Biochim. Biophys. Acta 45: 413−421
  128. Bennett R. M., Eddie-Quartey A. C. and Holt P. (1973) Lactoferrin an iron binding protein in synovial fl uid. Arthritis Rheum. 16: 186−190
  129. Maaks S., Yan II. Z. and Wood W. G. (1989) Development and evaluation of luminescence based sandwich assay for plasma lactoferrin as a marker for sepsis and bacterial infections in pediatric medicine. J. Biolumines. Chemilumines. 3: 221−226
  130. Debanne M.T., Regoeczi E., Sweeney G.D. and Krestynski F. (1985) Interaction of human lactoferrin with the rat liver. Am. J. Physiol. 248: G463—469
  131. Thomas L. L., Xu W. and Ardon Π’. T. (2002) Immobilized lactoferrin is a stimulus for eosinophil activation. J. Immunol. 169: 993−999
  132. Π‘. Π’. (2002) Lactoferrin gene expression and regulation: an overview. Biochem. Cell Biol. 80: 7−16
  133. Liu, D., Wang, X., Zhang, Z., & Teng, Π‘. T. (2003). An intronic alternative promoter of the human lactoferrin gene is activated by Ets. Biochemical and Biophysical Research Communications, 301, 472—479.
  134. , Π‘. T. (2006). Factors regulating lactoferrin gene expression. Biochemistry and Cell Biology, 84, 263−267.
  135. Ward, P. P., Paz, E., & Conneely, О. M. (2005). Multifunctional roles of lactoferrin: A critical overview. Cellular and Molecular Life Sciences, 62, 2540−2548.
  136. Rey, M. W., Woloshuk, S. L., deBoer, H. A., & Pieper, F. R. (1990). Complete nucleotide sequence of human mammary gland lactoferrin. Nucleic Acids Research, 18, 5288.
  137. Baker, E. N.,&Baker, H. M. (2005). Molecular structure, binding properties and dynamics of lactoferrin. Cellular and Molecular Life Sciences, 62, 2531—2539.
  138. , Π‘. Π’., and Gladwell, W. (2006). Single nucleotide polymorphisms (SNPs) in human lactoferrin gene. Biochemistry and Cell Biology, 84, 381−384.
  139. Spik, G., Coddeville, Π’., & Montreuil, J. (1988). Comparative study of the primary structures of sero-, lacto- and ovotransferrin glycans from different species. Biochimie, 70, 1459−1469.
  140. Wally J, Halbrooks PJ, Vonrhein Π‘ et al (2006) The crystal structure of iron-free human serum transferrin provides insight into inter-lobe communication and receptor binding. J Biol Chem 281:24 934−24 944
  141. Okamoto I, Mizutani K, Hirose M (2004) Iron-binding process in the amino- and carboxyl-terminal lobes of ovotransferrin: quantitative studies utilizing single Fe3(-binding mutants. Biochemistry 43:11 118−11 125
  142. Frazer D. M. and Anderson G. J. (2003) The orchestration of body iron intake: how and where do enterocytes receive their cues? Blood Cells Mol. Dis. 30: 288—297
  143. Iyer S. and Lonnerdal B. (1993) Lactoferrin, lactoferrin receptors and iron metabolism. Eur. J. Clin. Nutr. 47: 232−241
  144. M. D., Trenor Π‘. C. 3rd, Su M.A., Foernzler D., Beier D. R., Dietrich W. F. et al. (1997) Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat. Genet. 16: 383−386
  145. Suzuki Y. A., Shin K. and Lonnerdal B. (2001) Molecular cloning and functional expression of a human intestinal lactoferrin receptor. Biochemistry 40: 15 771−15 779
  146. N. C. (2000) Iron homeostasis: insights from genetics and animal models. Nat. Rev. Genet. 1: 208−217
  147. Sanchez L., Calvo M. and Brock J. H. (1992) Biological role of lactoferrin. Arch. Dis. Child. 67: 657−661 38. Davidson L. A. and Lonnerdal B. (1987) Persistence of human milk proteins in the breast-fed infant. Acta Paediatr. Scand. 76: 733−740
  148. Davidsson L., Kastenmayer P., Yuen M., Lonnerdal B. and Hurrell R. F. (1994) Infl uence of lactoferrin on iron absorption from human milk in infants. Pediatr. Res. 35: 117−124
  149. Ward P. P., Mendoza-Meneses M., Cunningham G. A. and Conneely О. M. (2003) Iron status in mice carrying a targeted disruption of lactoferrin. Mol. Cell. Biol. 23: 178−185
  150. N. (2004) The antimicrobial activity of lactoferrin: current status and perspectives. Biometals 17: 189−196
  151. Levay P. F. and Viljoen M. (1995) Lactoferrin: a general review. Haematologica 80: 252−267
  152. Arnold R. R., Cole M. F. and McGhee J. R. (1977) A bactericidal effect for human lactoferrin. Science 197: 263−265
  153. R. T. 3rd, Giehl T. J. and LaForce F. M. (1988) Damage of the outer membrane of enteric gram-negative bacteria by lactoferrin and transferrin. Infect. Immun. 56: 2774−2781
  154. Wakabayashi H., Takase M. and Tomita M. (2003) Lactoferricin derived from milk protein lactoferrin. Curr. Pharm. Des. 9: 1277−1287
  155. Singh P. K., Parsek M. R., Greenberg E. P. and Welsh M. J. (2002) A component of innate immunity prevents bacterial biofi lm development. Nature 417: 552—555
  156. Π’. E., Hayek M. Π’., Doebbeling B. N. and Fick R. B. Jr (1993) Transferrin and lactoferrin undergo proteolytic cleavage in the Pseudomonas aeruginosa-infected lungs of patients with cystic fl brosis. Infect. Immun. 61: 5049−5055
  157. Gomez H. F., Ochoa T. J., Carlin L. G. and Cleary T. G. (2003) Human lactoferrin impairs virulence of Shigella fl exneri. J. Infect. Dis. 187: 87—95
  158. Hendrixson D. R., Qiu J., Shewry S. C., Fink D. L., Petty S., Baker E. N. et al. (2003) Human milk lactoferrin is a serine protease that cleaves Haemophilus surface proteins at arginine-rich sites. Mol. Microbiol. 47: 607−617
  159. C., Mclnnes I. Π’., Vaughan D. M., Kommajosyula S., Van Berkel P. H., Leung B. P. et al. (2002) Enhanced Thl response to Staphylococcus aureus infection in human lactoferrin- transgenic mice. J. Immunol. 168: 3950−3957
  160. Shaper M., Hollingshead S. K., Benjamin W. H. Jr and Briles D. E. (2004) PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin. Infect. Immun. 72: 5031−5040
  161. А. Π’., Bonnah R., Yu R. H., Wong H. and Retzer M. (1998) Bacterial lactoferrin receptors. Adv. Exp. Med. Biol. 443: 123—133
  162. Dial E. J. and Lichtenberger L. M. (2002) Effect of lactoferrin on Helicobacter felis induced gastritis. Biochem. Cell Biol. 80: 113−117
  163. Kruzel M. L., Harari Y., Chen C. Y. and Castro G. A. (2000) Lactoferrin protects gut mucosal integrity during endotoxemia induced by lipopolysaccharide in mice. Infl animation 24: 33−44
  164. Lee W. J., Farmer J. L., Hilty M. and Kim Y. B. (1998) The protective effects of lactoferrin feeding against endotoxin lethal shock in germfree piglets. Infect. Immun. 66: 1421−1426
  165. Haversen L., Ohlsson B. G., Hahn-Zoric M., Hanson L. A. and Mattsby-Baltzer I. (2002) Lactoferrin down-regulates the LPSinduced cytokine production in monocytic cells viaNF-kappa B. Cell. Immunol. 220: 83−95
  166. Kaisho T. and Akira S. (2004) Pleiotropic function of Toll-like receptors. Microbes Infect. 6: 1388−1394
  167. Britigan Π’. E., Lewis T. S., Waldschmidt M., McCormick M. L. and Krieg A. M. (2001) Lactoferrin binds CpG-containing oligonucleotides and inhibits their immunostimulatory effects on human Π’ cells. J. Immunol. 167: 2921−2928
  168. Cumberbatch M., Bhushan M., Dearman R. J., Kimber I. and Griffi ths Π‘. E. (2003) IL-lbeta-induced Langerhans' cell migration and TNF-alpha production in human skin: regulation by lactoferrin. Clin. Exp. Immunol. 132: 352−359
  169. Haversen L. A., Baltzer L., Dolphin G., Hanson L. A. and Mattsby-Baltzer I.2003) Anti-infl ammatory activities of human lactoferrin in acute dextran sulphate-induced colitis in mice. Scand. J. Immunol. 57: 2−10
  170. Dial E. J., Dohrman A. J., Romero J. J. and Lichtenberger L. M. (2005) Recombinant human lactoferrin prevents NSAIDinduced intestinal bleeding in rodents. J. Pharm. Pharmacol. 57: 93−99
  171. Hayashida К., Kaneko Π’., Takeuchi Π’., Shimizu H., Ando K. and Harada E.2004) Oral administration of lactoferrin inhibits infl ammation and nociception in rat adjuvant-induced arthritis. J. Vet. Med. Sci. 66: 149−154
  172. Birgens H. S., Karle H., Hansen N. E. and Ostergaard Kristensen L. (1984) Lactoferrin receptors in normal and leukaemic human blood cells. Scand. J. Haematol. 33: 275−280
  173. Birgens H. S., Hansen N. E., Karle H. and Kristensen L. O. (1983) Receptor binding of lactoferrin by human monocytes. Br. J. Haematol. 54: 383−391
  174. Van Snick J. L. and Masson P. L. (1976) The binding of human lactoferrin to mouse peritoneal cells. J. Exp. Med. 144: 1568−1580
  175. Ward P. P., Uribe-Luna S. and Conneely О. M. (2002) Lactoferrin and host defense. Biochem. Cell Biol. 80: 95−102
  176. C., Mclnnes I. Π’., Vaughan D., Speekenbrink A. B. and Brock J. H. (2000) The effects of local administration of lactoferrin on infl ammation in murine autoimmune and infectious arthritis. Arthritis Rheum. 43: 2073−2080
  177. Elrod К. C., Moore W. R., Abraham W. M. and Tanaka R. D. (1997) Lactoferrin, a potent tryptase inhibitor, abolishes latephase airway responses in allergic sheep. Am. J. Respir. Crit. Care Med. 156: 375−381
  178. Wolf J. S., Li D., Taylor R. J. and O’Malley B. W. Jr (2003) Lactoferrin inhibits growth of malignant tumors of the head and neck. ORL J. Otorhinolaryngol Relat. Spec. 65: 245−249
  179. Shimamura M., Yamamoto Y., Ashino H., Oikawa Π’., Hazato Π’., Tsuda H. et al.2004) Bovine lactoferrin inhibits tumorinduced angiogenesis. Int. J. Cancer. Ill: 111−116
  180. Tsuda H., Sekine K., Fujita K. and Ligo M. (2002) Cancer prevention by bovine lactoferrin and underlying mechanisms — a review of experimental and clinical studies. Biochem. Cell Biol. 80: 131−136
  181. Tanaka Π’., Kawabata K., Kohno H., Honjo S., Murakami M., Ota T. et al. (2000) Chemopreventive effect of bovine lactoferrin on 4-nitroquinoline 1-oxide-induced tongue carcinogenesisin male F344 rats. Jpn. J. Cancer Res. 91: 25—33
  182. Masuda C., Wanibuchi H., Sekine K., Yano Y., Otani S., Kishimoto T. et al. (2000) Chemopreventive effects of bovine lactoferrin on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced rat bladder carcinogenesis. Jpn. J. Cancer Res. 91: 582 588
  183. Varadhachary A., Wolf J. S., Petrak K., O’Malley B. W. Jr, Spadaro M., Curcio C. et al. (2004) Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy. Int. J. Cancer 111: 398−403
  184. Kuhara Π’., Iigo M., Itoh Π’., Ushida Y., Sekine K., Terada N. et al. (2000) Orally administered lactoferrin exerts an antimetastatic effect and enhances production of IL-18 in the intestinal epithelium. Nutr. Cancer 38: 192−199
  185. Benaissa M, Peyrat JP, Hornez L, Mariller C, Mazurier J, Pierce A.2005)Expression and prognostic value of lactoferrin mRNA isoforms in human breast cancer. Int J Cancer. (2005) Mar 20- 114(2):299−306.
  186. Xiao Y., Monitto C. L., Minhas К. M. and Sidransky D. (2004) Lactoferrin down-regulates G1 cyclin-dependent kinases during growth arrest of head and neck cancer cells. Clin. Cancer Res. 10: 8683−8686
  187. Oh S. M., Pyo C. W., Kim Y. and Choi S. Y. (2004) Neutrophil lactoferrin upregulates the human p53 gene through induction of NF-kappaB activation cascade. Oncogene 23: 8282−8291
  188. Fujita K., Matsuda E., Sekine K., Iigo M. and Tsuda H. (2004) Lactoferrin enhances Fas expression and apoptosis in the colon mucosa of azoxymethane-treated rats. Carcinogenesis 25: 1961−1966
  189. Legrand D., Vigie K., Said E. A., Elass E., Masson M., Slomianny M. C. et al. (2004) Surface nucleolin participates in both the binding and endocytosis of lactoferrin in target cells. Eur. J. Biochem. 271: 303—317
  190. Damiens E., Mazurier J., el Yazidi I., Masson M., Duthille I., Spik G. et al. (1998) Effects of human lactoferrin on NK cell cytotoxicity against haematopoietic and epithelial tumour cells. Biochim. Biophys. Acta 1402: 277−287
  191. Bezault J., Bhimani R., Wiprovnick J. and Furmanski P. (1994) Human lactoferrin inhibits growth of solid tumors and development of experimental metastases in mice. Cancer Res. 54: 2310−2312
  192. Wang B, Fujisawa H, Zhuang L, Freed I, Howell BG, Shahid S, Shivji GM, Мак TW, Sauder DN, (2000). CD4+ Thl and CD8+ type 1 cytotoxic T cells both play a crucial role in the full development of contact hypersensitivity. J Immunol. 15−165(12):6783−90.
  193. P. (2004) Interleukin-18: recent advances. Curr. Opin. Hematol. 11: 405 410
  194. Lorget F, Clough J, Oliveira M, Daury MC, Sabokbar A, Offord E, (2002). Lactoferrin reduces in vitro osteoclast differentiation and resorbing activity. Biochem Biophys Res Commun. 16−296(2):261−6.
  195. Cornish J., Callon К. E., Naot D., Palmano K. P., Banovic Π’., Bava U. et al. (2004) Lactoferrin is a potent regulator of bone cell activity and increases bone formation in vivo. Endocrinology 145: 4366−4374
  196. Grey A., Banovic Π’., Zhu Q., Watson M., Callon K., Palmano K. et al. (2004) The low-density lipoprotein receptor-related protein 1 is a mitogenic receptor for lactoferrin in osteoblastic cells. Mol. Endocrinol. 18: 2268−2278
  197. Hashizume S., Kuroda K. and Murakami H. (1983) Identifi cation of lactoferrin as an essential growth factor for human lymphocyticcell lines in serum-free medium. Biochim. Π’iophys. Acta 763: 377−382
  198. Zakharova ET, Shavlovski MM, Bass MG, Gridasova AA, Pulina MO, De Filippis V, Beltramini M, Di Muro P, Salvato B, Fontana A, Vasilyev VB, Gaitskhoki VS.(2000)Interaction of lactoferrin with ceruloplasmin. Arch Biochem Biophys. 15−374(2):222−8.
  199. Perraudin JP, Prieels JP. (1982) Lactoferrin binding to lysozyme-treated Micrococcus luteus. Biochim Biophys Acta. 17−718(l):42−8.
  200. Lehrer RI, Rosenman M, Harwig SS, Jackson R, Eisenhauer P.(1991) Ultrasensitive assays for endogenous antimicrobial polypeptides. J Immunol Methods. 1991 Mar 21−137(2):167−73.
Π—Π°ΠΏΠΎΠ»Π½ΠΈΡ‚ΡŒ Ρ„ΠΎΡ€ΠΌΡƒ Ρ‚Π΅ΠΊΡƒΡ‰Π΅ΠΉ Ρ€Π°Π±ΠΎΡ‚ΠΎΠΉ